Challenging Ozonolysis

这项提议旨在提供突破性技术，以利用一些潜在的非常有价值的反应，这些反应由于传统实验室硬件的限制而很少在制药行业使用。重点是臭氧分解反应，其特点是对环境的影响最小，效率很高。尽管有这些特性，但由于安全方面的考虑，它们尚未得到广泛应用。微通道连续流动反应器为解决这些问题提供了极好的解决方案。这主要是由于存在较小的传质/热传递和淬火距离，以及改进的热管理。臭氧化反应是一种动力学快、放热高的多相反应，目前在商业流动化学系统中还不能进行。在多相反应中，来自一相的反应物必须通过界面，溶解，然后在另一相中反应。输运现象对反应性能起着至关重要的作用。因此，反应的行为(这是化学家的主要领域)与传输现象(化学工程师的主要领域)密不可分地联系在一起。因此，成功开发用于多相反应的流动化学系统和协议需要这两个学科的投入。在本提案中，我们致力于通过两个在有机合成和微反应技术方面有良好记录的研究团队和两个在药物化学和流动化学仪器方面具有专业知识的工业合作伙伴合作，开发新颖、易用、本质安全、连续流动的微通道反应器系统。基于臭氧作为氢化物受体的化学基础上，我们的目标是寻找和开发全新的、更绿色、高效和省力的合成途径，这些途径可以用来从廉价的原材料中生产与制药行业相关的高价值化合物。

This proposal is aimed at delivering breakthrough technology for exploiting a number of potentially very valuable reactions that are rarely used in the pharmaceutical industry due to constraints posed by conventional laboratory hardware. The focus is on ozonolysis reactions which are characterised by minimal environmental impact and high efficiency. In spite of these attributes they have not found widespread applications due to safety concerns. Micro channel continuous flow reactors offer an excellent solution to these issues. This is due mainly to the small distances present for mass / heat transfer and quenching, and improved heat management. Ozonolysis is an example of multiphase reactions with fast kinetics and high exothermicity, which can not be performed currently in commercially available flow chemistry systems. In multiphase reactions, reactants from one phase have to pass through an interface, dissolve and then react in another phase. Transport phenomena play a crucial role in reaction performance. Thus, the behaviour of the reaction (which is the prime domain of the chemist) is inexorably linked with transport phenomena (which are the prime domain of the chemical engineer). For this reason, successful development of flow chemistry systems and protocols for multiphase reactions requires input from both disciplines.In this proposal we endeavour to develop novel, easy to use, intrinsically safe, continuous flow, microchannel reactor systems, via collaboration between two research teams with strong track records in organic synthesis and microreaction technology and two industrial partners with expertise in medicinal chemistry and flow chemistry instrumentation. Based on the chemistry of ozone as a hydride acceptor, we aim to identify and exploit completely new, greener, highly efficient and less laborious synthesis pathways that can be employed to manufacture high value compounds of relevance to the pharmaceutical industry from inexpensive raw materials.